Background: Monitoring of minimal residual disease (MRD) in patients with hematological malignancies is important for evaluating the patients' therapeutic response and risk of relapse. Single nucleotide mutations associated with leukemogenesis can be considered as applicable MRD markers.
Introduction
In patients with hematological malignancies, minimal residual disease (MRD) status is correlated with the clinical outcome, and monitoring of MRD during chemotherapy and after hematopoietic stem cell transplantation (HSCT) is important in evaluating the patients' therapeutic response and the risk of relapse. The targets frequently used for MRD detection are fusion gene transcripts such as RUNX1-RUNX1T1, CBFB-MYH11, and PML-RARA resulting from t(8;21)(q22;q22), inv(16)(p13q22) or t(16;16)(p13;q22), and t(15;17)(q22;q12) [1] . In addition to the recurrent reciprocal translocations associated with leukemogenesis, a number of genetic alterations such as insertion, interstitial/partial tandem duplication, and single nucleotide mutation have been reported to be involved in the pathogenesis of leukemia and associated with the prognosis of the affected patients [2, 3] . Recently, several groups have performed quantitative assessment of NPM1 or FLT3 mutations and used them as MRD markers in patients with acute myelogenous leukemia [4] [5] [6] [7] [8] [9] [10] . NPM1 mutations are mainly characterized by tetranucleotide insertion. The quantitative assessments of the NPM1 mutation were performed by using TaqMan systems or LightCycler assays using primers or probes specific for the duplicated tetranucleotide. FLT3 mutations consist of 2 major types: internal tandem duplication and a missense point mutation in the tyrosine kinase domain. Quantitative assessments of FLT3-internal tandem duplication have been reported using the assay similarly to that for assessment of NPM1 mutations. According to the review by Renneville et al. [3] , single nucleotide mutations of genes such as KIT, FLT3, RAS, and PTPN11; RUNX1 and CEBPA; and TP53 are involved in proliferative advantage, impairment of hematopoietic AS-qPCR for monitoring MRD 4 differentiation, and regulation of cell cycle and apoptosis, respectively. These single nucleotide mutations can be considered as applicable targets for monitoring MRD.
However, a few studies have reported the quantitative assessments of single nucleotide mutations as compared to those that have reported insertions/duplications.
Recently, several studies have reported that single nucleotide mutations of JAK2 and MPL, or BCR-ABL were quantitatively monitored in myelofibrosis patients following transplantation [11] [12] [13] , or in chronic myelogenous leukemia patients with imatinib resistance, respectively [14, 15] . The detection of single nucleotide mutations in excess amount of wild-type nucleotides is more complicated than that of insertions/duplications involving several nucleotides. Allele-specific quantitative polymerase chain reaction (AS-qPCR) based on the amplification refractory mutation system (ARMS) or mismatch amplification mutation assay (MAMA) has been developed for quantification of single nucleotide mutations [16] [17] [18] . To obtain high specificity and sensitivity of the AS-qPCR, improvements, including the modification of primers and/or probes and additional procedures with restriction enzymes to digest residual wild-type nucleotides are required [19] [20] [21] . The AS-qPCR for single nucleotide mutations seems to be a useful method for the assessment of MRD.
In the present study, to evaluate whether AS-qPCR for single nucleotide mutations can be used for precise monitoring of MRD, we developed AS-qPCRs for FLT3 2503G > T, KIT 2446G > T, or KIT 2447A > T and compared the change in the expression levels of the FLT3 or KIT mutations assessed by AS-qPCR to those of RUNX1-RUNX1T1 fusion gene and WT1, which were assessed using conventional quantitative PCR (qPCR).
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Materials and methods
Patients and controls
We performed the present study using bone marrow (BM) cells obtained from 4 t(8;21)-positive acute myeloid leukemia (AML) patients carrying gene mutations (1 with FLT3 2503G > T, 1 with KIT 2446G > T, and 2 with KIT 2447A > T) ( Table 1) .
Ten BM samples from persons without hematological malignancies were used as normal controls. This study was approved by the institutional review board of the Shinshu University. Informed consent was obtained from the patients or guardians of the patients following institutional guidelines. 
Total
Construction of plasmids carrying wild-type or mutant FLT3 and KIT
To construct plasmids carrying the wild-type FLT3 or KIT, PCR products obtained by amplification of cDNA samples from normal controls were cloned into a pCR2.1 vector using the TA cloning kit (Invitrogen, Paisley, UK). Plasmids carrying the FLT3 2503G > T, KIT 2446G > T, or KIT 2447A > T mutation were then synthesized from the AS-qPCR for monitoring MRD 6 wild-type plasmids by oligonucleotide-directed mutagenesis using a site-directed mutagenesis kit (Stratagene, La Jolla, CA). The nucleotide sequences of the wild-type and mutant plasmids were confirmed by direct sequencing from both directions on an automatic DNA sequencer (ABI3100 Genetic Analyzer, Applied Biosystems, Foster City, CA).
Design of the primers for the FLT3 or KIT mutations in 3 types of AS-qPCR
Three different mutation-specific primers for the FLT3 or KIT mutations were designed as follows: mutant AS-qPCR primers including only a mutant-matched nucleotide in the 3′-end; mismatched AS-qPCR primers including a mutant-matched nucleotide in the 3′-end and a template-mismatched nucleotide at the penultimate 3′-end; locked nucleic acid (LNA)-AS-qPCR primers including a mutant-matched nucleotide in the 3′-end, a template-mismatched nucleotide at the penultimate 3′-end, and LNA at the -2 position from the 3′-end (Table 2) [19, 21] .
AS-qPCR
TaqMan probes, including fluorescein amidite (FAM) at the 5′-end nucleotide and a quencher (tetramethylrhodamine, TAMRA) at the 3′-end nucleotide, were exploited to assess the specificity and sensitivity of the AS-qPCR. The AS-qPCR reaction mixture contained cDNA (corresponding to 100 ng RNA), 1× TaqMan Universal PCR Master Mix (Applied Biosystems), 0.5 μmol/L of each primer, and 0.25 μmol/L of TaqMan probe in a total of 50 μL. The AS-qPCR was performed using an ABI PRISM 7900
Sequence Detection System (Applied Biosystems) at 50°C for 2 min, 95°C for 10 min, followed by 50 cycles at 95°C for 15 sec and 60°C for 1 min. To examine the AS-qPCR for monitoring MRD 7 specificity of the 3 types of AS-qPCR to discriminate between wild-type and mutant plasmid DNA, the difference of the threshold cycles (ΔCt) was calculated as follows:
(Ct for mutant plasmid) -(Ct for wild-type plasmid) in each AS-qPCR assay. To investigate the sensitivity for mutant plasmid DNA of the mismatched AS-qPCR and LNA-AS-qPCR, the delay in Ct (delay Ct) was calculated as follows: (Ct for mutant plasmid in mismatched AS-qPCR or LNA-AS-qPCR) -(Ct for mutant plasmid in mutant AS-qPCR) [19, 21] . The expression levels of the FLT3 or KIT mutations, RUNX1-RUNX1T1 fusion gene, or WT1 were normalized with respect to the expression of the abelson (ABL) gene, and expressed as copy numbers every 10 4 copies of ABL [22] . Each AS-qPCR assay for an individual patient was performed in triplicate.
Detection limit of the AS-qPCR for FLT3 and KIT mutations or qPCR for
RUNX1-RUNX1T1 fusion gene, and normal expression level of WT1
To determine the detection limit of the AS-qPCR, cDNA obtained from patients at diagnosis were serially 10-fold diluted in pooled cDNA from healthy controls, and the AS-qPCR was performed using the diluted samples [23] . In patient 2, the sample at diagnosis was not available and thus, the BM sample after chemotherapy was used to determine the detection limit. The normal expression level of WT1 was determined using BM samples from persons without hematological malignancies.
Quantification of RUNX1-RUNX1T1 fusion gene and WT1
The expression levels of the RUNX1-RUNX1T1 fusion gene or WT1 were quantified by conventional qPCR using the cDNA of the same time point as that used for the AS-qPCR [1, 24] .
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Statistics
Analysis of variance (ANOVA) was used for the comparisons of ΔCt among the 3 types of AS-qPCR, and unpaired t-test was used for the comparisons of delay Ct between mismatched AS-qPCR and LNA-AS-qPCR; p < 0.05 was considered to be significant.
Results
Characterization of mutant AS-qPCR, mismatched AS-qPCR, and
LNA-AS-qPCR
Using equal copy numbers of the constructed wild-type and mutant plasmids, the ΔCt was examined in the mutant AS-qPCR, mismatched AS-qPCR, and LNA-AS-qPCR AS-qPCR for monitoring MRD 9
Detection limit of the AS-qPCR for FLT3 and KIT mutations or qPCR for the
RUNX1-RUNX1T1 fusion gene, and normal expression level of WT1
The expression levels of FLT3 2503G > T or KIT 2447A > T at diagnosis in patient 1, 3, and 4 were 2.04 × 10 4 , 3.02 × 10 4 , and 4.43 × 10 4 , respectively (Fig. 2a, c, and d) .
The detection limits of FLT3 2503G > T or KIT 2447A > T in patient 1, 3, and 4 were 2.04 × 10, 3.02 × 10, and 4.43 × 10, respectively (Fig. 2a, c, and d) . As compared with the expression level at diagnosis, the mutations could be detected at a 10 3 -fold lower expression level. In patient 2 ( Fig. 2b) , a sample at diagnosis was not available;
therefore, a BM sample after chemotherapy was used to determine the detection limit.
The expression level of KIT 2446G > T in the BM sample after chemotherapy was 3.85 × 10 3 and the detection limit was 3.85 × 10; thus, the mutation could be detected at a respectively (Fig. 2) . The mean expression level of WT1 in 10 normal controls was (5.96 ± 4.63) × 10 ( Fig. 2) . 
Comparison of the change in the expression levels of FLT3 2503G > T, KIT
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level of KIT 2447A > T was below the detection limit and retained at that level until now. In patient 4 ( Fig. 2d) , after HSCT, the expression levels of KIT 2447A > T and the RUNX1-RUNX1T1 fusion gene decreased 10 3 -fold and that of WT1 decreased 40-fold. However, the expression of both KIT 2447A > T and the RUNX1-RUNX1T1 fusion gene have been detected at the level of 10 to 10 2 at 11 months after HSCT.
Discussion
In the present study, we developed AS-qPCRs to quantify leukemia-associated single nucleotide mutations in genes such as FLT3 and KIT, and evaluated the AS-qPCR to monitor MRD during chemotherapy and post-HSCT by comparison with the qPCR for the RUNX1-RUNX1T1 fusion gene and WT1.
Several allele-specific PCR methods based on ARMS or MAMA have been developed for the detection of single nucleotide mutations [16, 17] . The primers included a mutant-matched nucleotide at the 3′-end and a template-mismatched nucleotide near the 3′-end. Subsequently, an AS-qPCR based on ARMS or MAMA was developed to quantify low levels of mutant nucleotides in the presence of high levels of the counterpart wild-type nucleotides [18] . To increase the selectivity of the AS-qPCR, our present methods utilized primers including template-mismatched nucleotides or template-mismatched nucleotides plus LNA-substituted nucleotides which increased the binding affinity compared to standard nucleotides [19, 21, [25] [26] [27] .
For all mutations evaluated in this study, the ΔCt in the LNA-AS-qPCR was more than 15 cycles and that in the mismatched AS-qPCR was more than 9 cycles (Fig. 1) . The LNA-AS-qPCR provided the highest selectivity for the 3 mutations. The LNA-AS-qPCR was used to monitor the FLT3 2503G > T and KIT 2446G > T
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mutations, and the mismatched AS-qPCR was used to monitor the KIT 2447A > T mutation. Accordingly, we developed adequate AS-qPCRs with high specificity and sensitivity for each mutation. persistently by non-quantitative PCR analysis, so that the quantitative analysis of fusion gene transcripts should be performed to evaluate MRD [28, 29] . At relapse, the increases in the expression of the FLT3 or KIT mutant gene by AS-qPCR were in accordance with that of the RUNX1-RUNX1T1 fusion gene by qPCR ( Fig. 2a and b) .
In some measurements during complete remission (CR) in patient 3, the expression of KIT 2447A > T was detected at quantifiable levels, while that of the RUNX1-RUNX1T1
AS-qPCR for monitoring MRD 13 fusion gene was below the detection limit (Fig. 2c) . The recent studies have shown that, in patients with t(8;21)-positive leukemia, the expression of both wild-type KIT and mutated KIT was significantly higher than that in patients with t(8;21)-negative leukemia [30, 31] . Therefore, during CR in patient 3, the over-expressed mutated KIT gene could be detected by the present AS-qPCR. The observation that patient 3 experienced a second relapse indicates that the AS-qPCR may be useful to monitor MRD for prediction of imminent relapse in patients with only a single nucleotide mutation as available MRD marker. In patient 4, although no clinical and hematological abnormalities have been observed after HSCT, both KIT 2447A>T and RUNX1-RUVX1T1 have been detected at quantifiable levels persistently, and there is a possibility of relapse at high risk (Fig. 2d) . Therefore, close follow up of patient 4
with AS-qPCR is requisite. To develop a single gene mutation as a MRD marker, the stability of the gene mutation itself during follow-up is needed to be validated.
WT1 transcripts have been reported as MRD marker in patients with no recurrent chromosomal or genetic abnormalities. There have been controversies regarding the significance of WT1 transcripts as MRD marker, because WT1 transcripts were detected not only in tumor cells but also in normal cells [32, 33] . RUNX1-RUX1T1-positive patients showed significantly lower WT1 expression than patients with other types of AML and normal individuals [34, 35] . In the present cases with the RUNX1-RUX1T1 fusion gene, the ABL-normalized WT1 expressions levels were in the range 10 2 -10 4 .
Although no decreases in the WT1 expression of more than 10 2 -fold were observed during CR, increases in the WT1 expression at relapse were paralleled to that of KIT 2446G > T or KIT 2447A > T and the RUNX1-RUX1T1 fusion gene (Fig. 2b and c) . A quality-controlled standardized approach has been developed for an accurate and
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reproducible quantification of WT1 expression [36] . For the wide application of the present AS-qPCR to monitor MRD in patients without recurrent chromosomal and genetic abnormalities, it should be required to compare the alteration in the quantity of the mutant gene to that of WT1 in a large number of patients.
The percentage of autologous cells (chimerism) analyzed by short tandem repeat-PCR (STR-PCR), which characterizes the origin of post-transplant hematopoiesis, has been used as a surrogate marker for MRD [37] . The change in the quantity of the mutation detected by AS-qPCR using genomic DNA corresponded with the change of chimerism by STR-PCR [21] . The AS-qPCR was more sensitive than the STR-PCR.
In our patients, the mutated gene could be quantified significantly by AS-qPCR even when the chimerism by STR-PCR was less than 5% or negative (data not shown).
In conclusion, the AS-qPCRs for single nucleotide mutations had comparable accuracy to qPCR for the RUNX1-RUNX1T1 fusion gene and WT1 and were applicable to monitor MRD throughout the clinical course including prior to transplantation and post-transplantation. The AS-qPCR for single nucleotide mutations may permit us to monitor MRD in patients that lack recurrent chromosomal abnormalities and the specific fusion gene, which broadens the spectrum of patients in whom MRD can be monitored.
Abbreviations: MRD, minimal residual disease; AS-qPCR, allele-specific quantitative polymerase chain reaction; HSCT, hematopoietic stem cell transplantation; ARMS, amplification refractory mutation system; MAMA, mismatch amplification mutation assay; AML, acute myeloid leukemia; LNA, locked nucleic acid; FAM, fluorescein amidite; TAMRA, tetramethylrhodamine; ABL, abelson; CR, complete remission.
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Figure Legends 
